[Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma].

Beijing Da Xue Xue Bao Yi Xue Ban

Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.

Published: June 2023

Objective: To analyze the clinicopathological features, molecular changes and prognostic factors in angioimmunoblastic T-cell lymphoma (AITL).

Methods: Sixty-one cases AITL diagnosed by Department of Pathology of Peking University Cancer Hospital were collected with their clinical data. Morphologically, they were classified as typeⅠ[lymphoid tissue reactive hyperplasia (LRH) like]; typeⅡ[marginal zone lymphoma(MZL)like] and type Ⅲ [peripheral T-cell lymphoma, not specified (PTCL-NOS) like]. Immunohistochemical staining was used to evaluate the presence of follicular helper T-cell (TFH) phenotype, proliferation of extra germinal center (GC) follicular dendritic cells (FDCs), presence of Hodgkin and Reed-Sternberg (HRS)-like cells and large B transformation. The density of Epstein-Barr virus (EBV) + cells was counted with slides stained by Epstein-Barr virus encoded RNA (EBER) hybridization on high power field (HPF). T-cell receptor / immunoglobulin gene (TCR/IG) clonality and targeted exome sequencing (TES) test were performed when necessary. SPSS 22.0 software was used for statistical analysis.

Results: Morphological subtype (%): 11.4% (7/61) cases were classified as type Ⅰ; 50.8% (31/61) as type Ⅱ; 37.8% (23/61) as type Ⅲ. 83.6% (51/61) cases showed classical TFH immunophenotype. With variable extra-GC FDC meshwork proliferation (median 20.0%); 23.0% (14/61) had HRS-like cells; 11.5% (7/61) with large B transformation. 42.6% (26/61) of cases with high counts of EBV. 57.9% (11/19) TCR/IG, 26.3% (5/19) TCR/IG, 10.5% (2/19) were TCR/IG, and 5.3% (1/19) TCR/IG. Mutation frequencies by TES were 66.7% (20/30) for , 23.3% (7/30) for mutation, 80.0% (24/30) for mutation, and 33.3% (10/30) mutation. Integrated analysis divided into four groups: (1) and co-mutation group (7 cases): 6 cases were type Ⅱ, 1 case was type Ⅲ; all with typical TFH phenotype; HRS-like cells and large B transformation were not found; (2) single mutation group (13 cases): 1 case was type Ⅰ, 6 cases were type Ⅱ, 6 cases were type Ⅲ; 5 cases without typical TFH phenotype; 6 cases had HRS-like cells, and 2 cases with large B transformation. Atypically, 1 case showed TCR/IG, 1 case with TCR/IG, and 1 case with TCR/IG; (3) and/or mutation alone group (7 cases): 3 cases were type Ⅱ, 4 cases were type Ⅲ, all cases were found with typical TFH phenotype; 2 cases had HRS-like cells, 2 cases with large B transformation, and atypically; (4) non-mutation group (3 cases), all were type Ⅱ, with typical TFH phenotype, with significant extra-GC FDC proliferation, without HRS-like cells and large B transformation. Atypically, 1 case was TCR/IG. Univariate analysis confirmed that higher density of EBV positive cell was independent adverse prognostic factors for both overall survival (OS) and progression free survival(PFS), (=0.017 and =0.046).

Conclusion: Pathological diagnoses of ALTL cases with HRS-like cells, large B transformation or type Ⅰ are difficult. Although TCR/IG gene rearrangement test is helpful but still with limitation. TES involving , , , 3 can robustly assist in the differential diagnosis of those difficult cases. Higher density of EBV positive cells counts in tumor tissue might be an indicator for poor survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258054PMC
http://dx.doi.org/10.19723/j.issn.1671-167X.2023.03.019DOI Listing

Publication Analysis

Top Keywords

hrs-like cells
28
large transformation
28
cases type
24
cases
21
type Ⅲ
20
tfh phenotype
20
type Ⅱ
20
cells large
16
group cases
16
typical tfh
16

Similar Publications

Lymphomas of T-follicular helper origin (T-follicular helper-cell lymphoma [TFHL]) are often accompanied by an expansion of B-immunoblasts, occasionally with Hodgkin/Reed-Sternberg-like (HRS-like) cells, making the differential diagnosis with classic Hodgkin lymphoma (CHL) difficult. We compared the morphologic, immunophenotypic, and molecular features of 15 TFHL and 12 CHL samples and discussed 4 challenging cases of uncertain diagnosis. Compared with CHL, TFHL disclosed more frequent sparing of subcortical sinuses, high-endothelium venule proliferation, dendritic cell meshwork expansion, T-cell atypia, and aberrant T-cell immunophenotype.

View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated a triplet therapy of chidamide, decitabine, and camrelizumab (CDP) in patients with relapsed/refractory classic Hodgkin lymphoma (cHL) who previously underwent DNA methyltransferase inhibitor decitabine plus anti-PD-1 therapy.
  • CDP treatment was well-received, with a 94% objective response rate and 50% of patients achieving complete response, even in those who initially resisted DP therapy.
  • Research using single-cell RNA sequencing revealed interactions between malignant cells and immunosuppressive T cells, indicating that CDP treatment enhances anti-tumor responses while reducing immunosuppressive effects, offering a promising approach to overcoming immunotherapy resistance.
View Article and Find Full Text PDF

Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients.

Chin J Cancer Res

October 2023

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Article Synopsis
  • This study investigates how genetic abnormalities can aid in diagnosing angioimmunoblastic T-cell lymphoma (AITL) and identifying reliable prognostic factors.
  • Researchers analyzed 53 AITL cases, focusing on morphological features, immunophenotypes, and the presence of certain cells, while also conducting targeted exome sequencing for mutations.
  • The findings suggest that genetic mutation data can significantly improve diagnosis and indicate that high-density EBER presence is associated with poorer overall and progression-free survival rates.
View Article and Find Full Text PDF

[Progressively transformed germinal center-like follicular T-cell lymphoma:a clinicopathological analysis of 14 cases].

Zhonghua Bing Li Xue Za Zhi

November 2023

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

To investigate the clinicopathologic features of progressively transformed germinal center-like follicular T-cell lymphoma (PTGC-like FTCL). The clinicopathologic data of 14 PTGC-like FTCL cases that were diagnosed at the Beijing Friendship Hospital Affiliated to the Capital Medical University from January 2017 to January 2022 were retrospectively collected. Clinicopathological features, immunophenotype, and Epstein-Barr virus (EBV) infection status were analyzed in these cases.

View Article and Find Full Text PDF

[Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma].

Beijing Da Xue Xue Bao Yi Xue Ban

June 2023

Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.

Objective: To analyze the clinicopathological features, molecular changes and prognostic factors in angioimmunoblastic T-cell lymphoma (AITL).

Methods: Sixty-one cases AITL diagnosed by Department of Pathology of Peking University Cancer Hospital were collected with their clinical data. Morphologically, they were classified as typeⅠ[lymphoid tissue reactive hyperplasia (LRH) like]; typeⅡ[marginal zone lymphoma(MZL)like] and type Ⅲ [peripheral T-cell lymphoma, not specified (PTCL-NOS) like].

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!